


Cellular and Animal Models of Neurodegenerative diseases

~ efficient evaluation of medicine ~


- ❑ Accumulation of abnormal protein that cause neurodegeneration
- ❑ Useful for the development and evaluation of medicines

◆ Neurodegenerative diseases: Aging and spread of abnormal protein

◆ Our disease models for screening



(Jucker M. & Walker L. C., Nature, 2013)





◆ Cellular models

“Accumulation” of abnormal protein as seen in patient’s brain

Tau

alpha-synuclein

TDP-43



No aggregation


(Nonaka et al., J Biol Chem. 2010)

Aggregation, Phosphorylation, Ubiquitination

◆ Ex. Search for drug candidate

Selection of compound suppressing TDP-43 aggregation from Prestwick Chemical Library

FACS (fluorescence activated cell sorting)



No aggregation

Aggregation

Untreated cells (Control)

Treated cells

Inhibition of aggregation

We found several candidate compounds that inhibit aggregation of abnormal TDP-43

1. Seed-dependent cellular models show the pathology of accumulation of abnormal protein, such as tau, alpha-synuclein, and TDP-43.
2. These models are useful for the evaluation of medicine that inhibit the progression of AD, DLB, PD, ALS, etc.





Animal models


"Propagation" of abnormal protein as seen in patient's brain

Tau

alpha-synuclein




Biochemical analysis of mouse brain injected abnormal α Syn




Human α Syn was transformed into mouse α Syn


Masuda-Suzukake et al, *Brain* 2013.



Tau pathology and staging of Alzheimer



Abnormal protein acquired "prion-like" feature?



Lab's web site

Tokyo metro. Inst. Med. Sci. Dementia project
URL: <http://www.igakuken.or.jp/dementia/>

Papers

- Masuda-Suzukake M, Nonaka T, Hosokawa M, Kubo M, Shimozawa A, Akiyama H, Hasegawa M. Pathological alpha-synuclein propagates through neural networks. *Acta Neuropathol Commun.* 2014 Aug 6;2:88.
- Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, Akiyama H, Mann DM, Hasegawa M. Prion-like spreading of pathological alpha-synuclein in brain. *Brain.* 2013 Apr;136(Pt 4):1128-38.
- Nonaka T, Watanabe ST, Iwatsubo T, Hasegawa M. Seeded aggregation and toxicity of alpha-synuclein and tau: cellular models of neurodegenerative diseases. *J Biol Chem.* 2010 Nov 5;285(45):34885-98.
- Nonaka T, Arai T, Buratti E, Baralle FE, Akiyama H, Hasegawa M. Phosphorylated and ubiquitinated TDP-43 pathological inclusions in ALS and FTLD-U are recapitulated in SH-SY5Y cells. *FEBS Lett.* 2009 Jan 22;583(2):394-400.
- Nonaka T, Kametani F, Arai T, Akiyama H, Hasegawa M. Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43. *Hum Mol Genet.* 2009 Sep 15;18(18):3353-64.

Patents

- Tdp-43-storing cell model, JP 5667872, US 8715643, 9128081, EP 2272955 DE,FR,GB
- Protein which can serve as nucleus for polymerization of protein polymer, cell having the polymer introduced therein, and process for production of the cell, JP 5665258, EP 1964918 DE,FR,GB
- The screening method of the neurodegenerative disease therapeutics, JP 4948845
- Antibody binding specifically to tdp-43 aggregate, JP 5439176, US 8940872, EP 2189526 BE,DE,FR,GB,NL
- Method for producing insoluble aggregate of neurodegenerative-disease-related protein, CN 201280044001.5



Yumiko Ogata, Manager,
Technology Licensing Office, Tokyo Metropolitan Institute of Medical Science
<http://www.igakuken.or.jp/tlo/> e-mail: chizai@igakuken.or.jp